Quantum Cyber N.V. current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K is filed by Mainz Biomed N.V. (not Quantum Cyber N.V. as indicated in metadata) for the month of January 2022, with the report dated January 28, 2022. The filing reports on the entry into a material definitive agreement regarding an underwritten public offering of ordinary shares.

Key Financial Metrics

The filing details a capital raise event rather than operational financial performance. Key metrics include:

  • Shares Sold: 1,725,000 ordinary shares (including 225,000 from the over-allotment option).
  • Offering Price: $15.00 per share.
  • Gross Proceeds: Approximately $25,875,000 (calculated as 1,725,000 shares x $15.00).
  • Net Proceeds: Approximately $23,529,700 after deducting underwriting discounts, commissions, and offering expenses.
  • Underwriting Fees: 7% cash fee plus 0.75% non-accountable expense allowance of gross proceeds.

The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.

Material Changes

The primary material change is the significant increase in cash liquidity resulting from the closing of the public offering on January 28, 2022. The company successfully exercised the full 15% over-allotment option, increasing the total shares sold beyond the initial 1,500,000.

Outlook, Risks, and Management Commentary

Management commentary is limited to the announcement of the offering pricing and the exercise of the over-allotment option via press releases attached as exhibits. The filing notes that representations and warranties in the Underwriting Agreement were made solely for the benefit of the contracting parties and may be subject to limitations. No specific forward-looking guidance, risk factors, or contingencies regarding future operations are detailed in this specific report.

Investor Verification Checklist

  • Verify the company name is Mainz Biomed N.V. and not Quantum Cyber N.V.
  • Confirm the use of the $23.5 million in net proceeds as disclosed in subsequent filings or press releases.
  • Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants or lock-up periods.
  • Check for any dilution impact on existing shareholders due to the issuance of 1,725,000 new shares.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.